[Stitcher]

Lundbeck Reports Results Of ADAGIO Study With Azilect

Published:24-September-2009
Azilect 1mg/day early-start met all endpoints of the primary analysis
http://www.oursocialmedia.com/uk/tev...iopublication/

Lundbeck's partner Teva has announced that results from the ADAGIO trial, which demonstrated that Parkinson's disease patients receiving Azilect (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group). The finding is consistent with a possible disease-modifying effect for Azilect 1mg/day.

The company claims that Azilect is the first Parkinson's disease treatment to succeed in a prospective delayed-start study, a trial design specifically developed to test for the possibility of a disease-modifying effect.

Professor C Warren Olanow, department of neurology at Mount Sinai School of Medicine, NY and co-principal investigator of the ADAGIO study, said: "A therapy that slows or stops disease progression is the greatest unmet need in the treatment of patients with Parkinson's disease. Current therapies do not prevent the development of disability in such patients. The results of the ADAGIO study provide support for the possibility that early treatment with Azilect 1mg/day may slow the development of disability."